An Emory University-led research collaboration has been awarded a five-year $23.8 million grant from the National Institutes of Health (NIH) to fast-track research to cure HIV infection or put it in permanent remission.
A report from the U.S. Department of Health and Human Services (HHS) has found that considerable increases in the use of telehealth helped maintain some healthcare access during the COVID- 19 pandemic,
Novartis has received U.S. Food and Drug Administration (FDA) approval for its Cosentyx (secukinumab) to treat children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.
Eltrombopay found to improve therapy for aplastic anemia.
Researchers at the University of Toledo have developed an experimental vaccine to prevent rheumatoid arthritis, one of the most common autoimmune disorders
Investigators found COVID-19 infection altered the mothers’ immunity at delivery, and gestational COVID-19 exposure alters the immunity of newborns.
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
The National Institutes of Health is conducting a $470 million study to determine why COVID-19 symptoms persist for so long among many patients.
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
